Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$417.86 USD

417.86
1,931,027

+3.85 (0.93%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field

by Zacks Equity Research

GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.

Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing

by Zacks Equity Research

Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.

Zacks Industry Outlook Highlights Elevance Health, Cencora and HealthEquity

by Zacks Equity Research

Elevance Health, Cencora and HealthEquity have been highlighted in this Industry Outlook article.

The Zacks Analyst Blog Highlights Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health

by Zacks Equity Research

Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Johnson & Johnson, Walt Disney & Uber

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

by Zacks Equity Research

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System

by Zacks Equity Research

Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.

Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.

Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth

by Zacks Equity Research

Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.

DexCom (DXCM) Launches One+ Real-time CGM System in Europe

by Zacks Equity Research

DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

by Zacks Equity Research

Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.

Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Inspire Medical's (INSP) U.S. region witnesses strong revenue growth in the fourth quarter.

Centene (CNC) Q4 Earnings Beat on Membership Growth, View Up

by Zacks Equity Research

Centene (CNC) expects adjusted EPS to be a minimum of $6.70 in 2024, higher than the 2023 figure of $6.68 per share.

Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT

by Zacks Equity Research

Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

ELV vs. AVTR: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. AVTR: Which Stock Is the Better Value Option?

Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.

BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.

Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.

HCA Healthcare's (HCA) Q4 Earnings Beat on Improved Admissions

by Zacks Equity Research

HCA Healthcare (HCA) expects EPS in the range of $19.70-$21.20 for 2024, the midpoint being 7.6% higher than the 2023 figure.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.